ArticleWorld journal of surgical oncology2026
Risk-adapted nodal evaluation in stage IA non-small cell lung cancer: a population-based competing-risk analysis.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe oncologic value of intensified lymph node (LN) evaluation in stage IA non-small cell lung cancer (NSCLC) remains uncertain in the era of surgical de-escalation. Although expanded nodal assessment may reduce understaging, whether it is associated with meaningful survival differences in this favorable-risk population is unclear. Clarifying this issue is essential to balance oncologic adequacy and surgical burden.
methodWe conducted a population-based cohort study using the Surveillance, Epidemiology, and End Results database and included patients with surgically treated pathologic stage IA (T1N0M0) NSCLC. The extent of nodal evaluation was quantified by the number of examined lymph nodes. Propensity score matching was used to balance baseline characteristics. Cancer-specific and other-cause death were analyzed using cumulative incidence functions and Fine-Gray competing-risk models. Prespecified subgroup analyses assessed heterogeneity of association, particularly according to tumor size.
resultsWe included 24,215 patients, with 13,812 after matching. Intensified nodal evaluation, defined as ≥ 6 examined lymph nodes (ELNs), was associated with lower cancer-specific mortality (5-year cumulative incidence, 12.9% vs. 15.3%; absolute risk reduction [ARR] 2.4%; Gray's P < 0.001). In multivariable Fine-Gray analysis, ELNs ≥ 6 remained independently associated with lower cancer-specific mortality (subdistribution hazard ratio 0.78, 95% CI 0.74-0.83). The association was minimal in tumors ≤ 1 cm but more evident in tumors > 1 cm. Sensitivity analyses using ELNs ≥ 10 yielded similar findings.
conclusionThe association between intensified nodal evaluation and lower cancer-specific mortality in stage IA NSCLC varies by tumor size. This association was more evident in tumors > 1 cm, supporting further investigation of a size-based, risk-adapted approach to surgical staging in early-stage NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.